经皮CT引导微波消融联合椎体增强术治疗疼痛性脊柱转移瘤
回顾性评估91例患者140节疼痛性转移椎体接受CT引导微波消融联合椎体增强术的效果与安全性;术后6个月内疼痛评分、吗啡日用量及ODI评分均下降(均P<.05),局部控制率94.8%,无症状骨水泥渗漏42节(30%),1例(1.1%)3级神经损伤经治疗后恢复正常。
要点
- 术后6个月内VAS评分、吗啡日用量及ODI评分均较术前下降,差异有统计学意义。
- 6个月随访期间局部肿瘤控制率为94.8%(按治疗的转移椎体计)。
- 无症状骨水泥渗漏见于42节(30%)治疗椎体,1例(1.1%)出现3级神经损伤。
核心结论
- CT引导经皮微波消融联合椎体增强术是治疗疼痛性脊柱转移瘤安全有效的微创介入方法。
研究设计与样本
- 回顾性研究,纳入91例患者共140节转移椎体,均接受CT引导微波消融联合椎体增强术。
- 纳入患者均有难治性中度至重度疼痛;术前及随访期间评估疼痛、吗啡用量和功能障碍。
- 随访影像用于评估局部肿瘤控制;原文未写明随访影像的具体检查方式。
关键影像表现/征象
- 随访影像评估局部肿瘤控制,6个月随访期间94.8%的治疗转移椎体达到局部控制。
- 无症状骨水泥渗漏发生于42节(30%)治疗椎体。
- 1例患者(1.1%)出现3级神经损伤,经甘露醇、糖皮质激素及放射治疗后神经功能恢复正常。
诊断标准与关键数值
- 疼痛评估采用视觉模拟量表(VAS):术前中位6分(范围4-10),术后3天5分(范围3-8),1周4分(范围2-7),1个月3分(范围1-6),3个月3分(范围1-6),6个月3分(范围1-8),均P<.05。
- 吗啡日用量:术前均值77.8 mg(SD 31.5,范围15-143),术后3天34.5 mg(SD 23.8,范围0-88),1周28.7 mg(SD 16.4,范围0-73),1个月24.6 mg(SD 13.2,范围0-70),3个月21.70 mg(SD 10.0,范围0-42),6个月21.0 mg(SD 9.9,范围0-46),均P<.05。
- Oswestry功能障碍指数评分下降(P<.01);原文未报告具体分值。
- 局部控制率按治疗的转移椎体计为94.8%(6个月随访期间)。
临床应用与阅片要点
- 术前及随访采用VAS、吗啡日用量和ODI评分量化疼痛与功能改变,随访影像评估局部肿瘤控制。
- 术后需关注骨水泥渗漏(本组无症状渗漏42节,30%)及神经损伤并发症(1例3级神经损伤,1.1%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Percutaneous thermal ablation followed by vertebral augmentation is an emerging minimally invasive therapeutic alternative for the management of spinal metastases. This study aimed to retrospectively evaluate the effectiveness and safety of microwave ablation combined with vertebral augmentation for the treatment of painful vertebral metastases.
MATERIALS AND METHODS: Overall, 91 patients with 140 metastatic vertebrae who experienced refractory moderate-to-severe pain were treated with CT-guided microwave ablation and vertebral augmentation. Procedural effectiveness was determined using the visual analog scale, daily morphine consumption, and the Oswestry Disability Index preprocedurally and during follow-up. Local tumor control was assessed at follow-up imaging.
RESULTS: The procedure was technically successful in all patients. The median visual analog scale score and mean morphine dose were 6 (range, 4-10) and 77.8 (SD, 31.5) mg (range, 15-143 mg), preprocedurally; 5 (range 3-8) and 34.5 (SD, 23.8) mg (range, 0-88 mg) at 3 days; 4 (range, 2-7) and 28.7 (SD, 16.4) mg (range, 0-73 mg) at 1 week; 3 (range, 1-6) and 24.6 (SD, 13.2) mg (range, 0-70 mg) at 1 month; 3 (range, 1-6) and 21.70 (SD, 10.0) mg (range, 0-42 mg) at 3 months; and 3 (range, 1-8) and 21.0 (SD, 9.9) mg (range, 0-46 mg) at 6 months postprocedurally (all P < .05). A decrease in the Oswestry Disability Index score was also observed (P < .01). Local control was achieved in 94.8% of the treated metastatic vertebrae during the 6-month follow-up period. Asymptomatic cement leakage occurred in 42 (30%) treated vertebrae. A grade 3 neural injury was observed in 1 patient (1.1%). The patient's neurologic function returned to normal following treatment with mannitol, glucocorticoids, and radiation therapy.
CONCLUSIONS: This study demonstrates that percutaneous CT-guided microwave ablation combined with vertebral augmentation is a safe and effective minimally invasive intervention for the treatment of painful spinal metastases.
引用
- Chen, Hou, Zhang, et al. Percutaneous CT-Guided Microwave Ablation Combined with Vertebral Augmentation for Treatment of Painful Spinal Metastases. AJNR Am J Neuroradiol. 2022. PMID: 35115308. doi:10.3174/ajnr.A7415
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。